Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $412.6 million.

  • Apellis Pharmaceuticals' Cash & Current Investments rose 20.69% to $480.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 12.89%. This contributed to the annual value of $412.6 million for FY2024, which is 17.12% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Cash & Current Investments stood at $412.6 million, which was up 17.12% from $352.3 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash & Current Investments peaked at $877.6 million during FY2020, and registered a low of $352.3 million during FY2023.
  • For the 3-year period, Apellis Pharmaceuticals' Cash & Current Investments averaged around $439.3 million, with its median value being $412.6 million (2024).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Cash & Current Investments plummeted by 36.30% in 2023, and later grew by 17.12% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash & Current Investments (Yearly) stood at $877.6 million in 2020, then decreased by 20.18% to $700.5 million in 2021, then dropped by 21.05% to $553.1 million in 2022, then plummeted by 36.30% to $352.3 million in 2023, then rose by 17.12% to $412.6 million in 2024.